Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study ...

Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ ...

Johnson & Johnson announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia ...

Please provide your email address to receive an email when new articles are posted on . Systemic corticosteroids can lead to CD4 lymphopenia and lower IgG levels. Rituximab therapy can lead to ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today presented positive topline data from Part 1 of ...

The study looked at patients from 12 to 18 years of age, in an open-label study, looking at the safety and efficacy of nipocalimab in this age group. We were able to show that nipocalimab was well ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced the presentation of preclinical data for its pan‑immunoglobulin G (IgG) sculpting ...

Researchers from Edith Cowan University (ECU) have developed an innovative new way to measure biological age, which could ...